Impact of Risk Feedback on Behavioral Trajectories

June 12, 2026 updated by: Susan Luczak, University of Southern California

Alcohol Metabolism and Disease Risk in Asians: Examining the Impact of Personalized Phenotypic/Genotypic Feedback on Early Drinking Trajectories

The goal of this study is to examine the effects of providing personalized information about behavioral, physical, and genetic factors that are associated with elevations in risk for some health problems. The main research question is: can we affect young adult behaviors through communication about these health-related risks? Participants will be asked to complete an in-person baseline session where they provide a DNA sample, complete online surveys, and do a brief interview. They will then receive one of several brief online information sessions and be followed in online surveys approximately every 3 months over the next 2 years.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

450

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Susan Luczak, PhD
  • Phone Number: 2137402203
  • Email: luczak@usc.edu

Study Locations

  • United States
    • California
      • Los Angeles, California, United States, 90089
        • University of Southern California
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • USC student of Chinese, Japanese, Korean, or Vietnamese heritage

Exclusion Criteria:

  • not a USC student, not 17-25 years old, not of Chinese, Japanese, Korean, or Vietnamese heritage

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PHEN
provided phenotypic feedback
Behavioral: PHEN feedback
Feedback on alcohol response (phenotype)
Experimental: GENE
provides genotypic feedback
Behavioral: PHEN feedback
Feedback on alcohol response (phenotype)
Genetic: PHEN+GENE Feedback
Feedback on both phenotype and genotype (PHEN+GENE)
Placebo Comparator: CONTROL
provided a control feedback
Other: Control
Feedback that serves as control

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Drinking frequency
Time Frame: up to 2 years post-intervention
Number of days consumed alcohol
up to 2 years post-intervention
Average alcohol quantity
Time Frame: up to 2 years post-intervention
Average amount of alcohol consumed on drinking days
up to 2 years post-intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Amount of alcohol consumed
Time Frame: up to 2 years post-intervention
Total number of drinks consumed
up to 2 years post-intervention
Maximum daily alcohol
Time Frame: up to 2 years post-intervention
Highest number of drinks consumed on one day
up to 2 years post-intervention
Use of flush cures
Time Frame: up to 2 years post-intervention
Proportion of drinking days used flush cures
up to 2 years post-intervention
Use of drinking behavioral strategies
Time Frame: up to 2 years post-intervention
Proportion of drinking days used behavioral strategies
up to 2 years post-intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Southern California

Collaborators

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Investigators

  • Principal Investigator: Susan Luczak, PhD, University of Southern California

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

August 18, 2026

Primary Completion (Estimated)

February 28, 2029

Study Completion (Estimated)

August 31, 2030

Study Registration Dates

First Submitted

June 9, 2026

First Submitted That Met QC Criteria

June 12, 2026

First Posted (Actual)

June 18, 2026

Study Record Updates

Last Update Posted (Actual)

June 18, 2026

Last Update Submitted That Met QC Criteria

June 12, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UP-24-00754
  • R01AA032036 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

For participants who agree to have their data included, de-identified participant data will be uploaded to the National Institute of Mental Health Data Archive (NDA).

IPD Sharing Time Frame

Data will be available no later than 2 years post-study completion and will be available indefinitely.

IPD Sharing Access Criteria

Access will be made in accordance with NDA regulations.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on PHEN feedback

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe